PDCD1 and hepatocellular carcinoma: A number of clinical trials evaluating the effect of anti-PD-1 immunotherapy in combination with LDT are underway as phase 1 trials for intermediate-advanced HCC not amenable for resection or OLT (NCT02837029, NCT03143270, and NCT03099564) with several phase two trials completed late 2019 (NCT03380130, NCT03033446) with results pending.